Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2009

View Archived Issues

Adenovirus-based prostate-specific antigen vaccine enters phase II trials for prostate cancer

Mechanism of action of HCV candidate drug PG-301029 under investigation

New gamma secretase inhibitors in early development at EnVivo Pharmaceuticals for AD

Novel casein kinase 1 inhibitors claimed by sanofi-aventis for the treatment of sleep disorders

Shionogi discloses novel compounds for the treatment of diabetes

New heterocyclic antiviral compounds discovered by Roche

Allergan claims alpha adrenoceptor agonists for the treatment of pain

Idenix reports new series of compounds for the treatment of hepatitis C

Bevacizumab combined with panretinal photocoagulation may be used in glaucoma therapy

Data show potential of Debio-025 in treating HCV genotypes 2, 3 and 4

SpePharm launches MuGard and Xerotin in Europe

Chugai and Roche describe development, preclinical and clinical investigation of CH-4987655

PharmaMar's alkaloid PM-01183 active in vivo, enters phase I investigation

Novel, orally active c-MET inhibitor discovered at Lilly: LY-2801653

BioMarin initiates phase I/II trial for BMN-110 in Morquio A syndrome

BioMS receives positive review from Data Safety Board for dirucotide in MS

Huya and Abbott form strategic alliance on drug candidates from China

Santhera enrolls last patient in phase IIb FJORD study in Parkinson's disease

Cytos initiates phase IIa study with CYT003-QbG10 in allergic asthma

Preclinical anticancer activity of MEK1 inhibitor E-6201 detailed at AACR

MediciNova reports phase II results for MN-221 in severe asthma exacerbations

Topica begins phase II luliconazole trial in athlete's foot

Daiichi Sankyo receives Japanese approval for new formulations of Cravit

Chugai receives approval in Japan for changes to API manufacturing of Epogin

Semafore achieves proof of concept in design of dual pathway kinase inhibitor SF-2626

UCT initiates phase IIb clinical trial of TB vaccine MVA-85A/AERAS-485 in South Africa

Nippon and Astellas granted manufacturing and marketing approval in Japan for Micombi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...